Association of CD34+ Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies

Yi Lun Wang; Tsung Yen Chang; Hsin Yi Hsieh; Shih Hsiang Chen; Yu Chuan Wen; Chia Chi Chiu; Tang Her Jaing

doi:10.1016/j.transproceed.2023.01.005

Association of CD34⁺ Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies

Yi Lun Wang
, Tsung Yen Chang
, Hsin Yi Hsieh
, Shih Hsiang Chen
, Yu Chuan Wen
, Chia Chi Chiu
, Tang Her Jaing^*

^*Corresponding author for this work

Chang Gung Memorial Hospital

Research output: Contribution to journal › Journal Article › peer-review

Abstract

BACKGROUND: A higher CD34 + cell dose is associated with improved engraftment but may also be associated with an increased risk of complications after allogeneic hematopoietic stem cell transplantation, including graft-versus-host disease (GVHD).

METHODS: We retrospectively analyze the impact of CD34 + cell dose on OS, PFS, neutrophil engraftment, platelet engraftment, treatment-related mortality, and GVHD grading.

RESULTS: For analyses, CD34 + cell dose was stratified into low (< 8.5 × 10 6/kg) and high (> 8.5 × 10 6/kg). A subgroup analysis of higher CD34 + cell dose leads to prolonged OS and PFS, but statistical significance was achieved only for PFS (OR 0.36; 95%CI 0.14-0.95; P = 0.04).

CONCLUSIONS: This study reinforced that CD34+ cell dose at the time of allo-HSCT retained a positive impact on PFS.

Original language	English
Pages (from-to)	481-484
Number of pages	4
Journal	Transplantation Proceedings
Volume	55
Issue number	2
DOIs	https://doi.org/10.1016/j.transproceed.2023.01.005
State	Published - 03 2023
Externally published	Yes

Bibliographical note

Keywords

Humans
Child
Progression-Free Survival
Retrospective Studies
Hematopoietic Stem Cell Transplantation/adverse effects
Hematologic Neoplasms/therapy
Graft vs Host Disease/etiology
Antigens, CD34/analysis

Access to Document

10.1016/j.transproceed.2023.01.005

Cite this

Wang, Y. L., Chang, T. Y., Hsieh, H. Y., Chen, S. H., Wen, Y. C., Chiu, C. C., & Jaing, T. H. (2023). Association of CD34⁺ Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies. Transplantation Proceedings, 55(2), 481-484. https://doi.org/10.1016/j.transproceed.2023.01.005

@article{0a40120d5061496cb768bb5fba83aeec,

title = "Association of CD34+ Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies",

abstract = "BACKGROUND: A higher CD34 + cell dose is associated with improved engraftment but may also be associated with an increased risk of complications after allogeneic hematopoietic stem cell transplantation, including graft-versus-host disease (GVHD). METHODS: We retrospectively analyze the impact of CD34 + cell dose on OS, PFS, neutrophil engraftment, platelet engraftment, treatment-related mortality, and GVHD grading. RESULTS: For analyses, CD34 + cell dose was stratified into low (< 8.5 × 10 6/kg) and high (> 8.5 × 10 6/kg). A subgroup analysis of higher CD34 + cell dose leads to prolonged OS and PFS, but statistical significance was achieved only for PFS (OR 0.36; 95\%CI 0.14-0.95; P = 0.04). CONCLUSIONS: This study reinforced that CD34+ cell dose at the time of allo-HSCT retained a positive impact on PFS.",

keywords = "Humans, Child, Progression-Free Survival, Retrospective Studies, Hematopoietic Stem Cell Transplantation/adverse effects, Hematologic Neoplasms/therapy, Graft vs Host Disease/etiology, Antigens, CD34/analysis",

author = "Wang, \{Yi Lun\} and Chang, \{Tsung Yen\} and Hsieh, \{Hsin Yi\} and Chen, \{Shih Hsiang\} and Wen, \{Yu Chuan\} and Chiu, \{Chia Chi\} and Jaing, \{Tang Her\}",

year = "2023",

month = mar,

doi = "10.1016/j.transproceed.2023.01.005",

language = "英语",

volume = "55",

pages = "481--484",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier Inc.",

number = "2",

}

Association of CD34⁺ Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies. / Wang, Yi Lun; Chang, Tsung Yen; Hsieh, Hsin Yi et al.
In: Transplantation Proceedings, Vol. 55, No. 2, 03.2023, p. 481-484.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Association of CD34+ Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies

AU - Wang, Yi Lun

AU - Chang, Tsung Yen

AU - Hsieh, Hsin Yi

AU - Chen, Shih Hsiang

AU - Wen, Yu Chuan

AU - Chiu, Chia Chi

AU - Jaing, Tang Her

PY - 2023/3

Y1 - 2023/3

N2 - BACKGROUND: A higher CD34 + cell dose is associated with improved engraftment but may also be associated with an increased risk of complications after allogeneic hematopoietic stem cell transplantation, including graft-versus-host disease (GVHD). METHODS: We retrospectively analyze the impact of CD34 + cell dose on OS, PFS, neutrophil engraftment, platelet engraftment, treatment-related mortality, and GVHD grading. RESULTS: For analyses, CD34 + cell dose was stratified into low (< 8.5 × 10 6/kg) and high (> 8.5 × 10 6/kg). A subgroup analysis of higher CD34 + cell dose leads to prolonged OS and PFS, but statistical significance was achieved only for PFS (OR 0.36; 95%CI 0.14-0.95; P = 0.04). CONCLUSIONS: This study reinforced that CD34+ cell dose at the time of allo-HSCT retained a positive impact on PFS.

AB - BACKGROUND: A higher CD34 + cell dose is associated with improved engraftment but may also be associated with an increased risk of complications after allogeneic hematopoietic stem cell transplantation, including graft-versus-host disease (GVHD). METHODS: We retrospectively analyze the impact of CD34 + cell dose on OS, PFS, neutrophil engraftment, platelet engraftment, treatment-related mortality, and GVHD grading. RESULTS: For analyses, CD34 + cell dose was stratified into low (< 8.5 × 10 6/kg) and high (> 8.5 × 10 6/kg). A subgroup analysis of higher CD34 + cell dose leads to prolonged OS and PFS, but statistical significance was achieved only for PFS (OR 0.36; 95%CI 0.14-0.95; P = 0.04). CONCLUSIONS: This study reinforced that CD34+ cell dose at the time of allo-HSCT retained a positive impact on PFS.

KW - Humans

KW - Child

KW - Progression-Free Survival

KW - Retrospective Studies

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Hematologic Neoplasms/therapy

KW - Graft vs Host Disease/etiology

KW - Antigens, CD34/analysis

UR - https://www.scopus.com/pages/publications/85149741241

U2 - 10.1016/j.transproceed.2023.01.005

DO - 10.1016/j.transproceed.2023.01.005

M3 - 文章

C2 - 36863969

AN - SCOPUS:85149741241

SN - 0041-1345

VL - 55

SP - 481

EP - 484

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 2

ER -